IP Library Granted Patent US 6,869,441
Granted Patent B2
US 6,869,441 · App. 10/394,782 · Granted Mar 22, 2005

Thermal therapy sleeve

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,869,441
App. No.
10/394,782
Granted
Mar 22, 2005
Kind
B2
Abstract

A flexible thermal therapy sleeve is disclosed. The sleeve includes a first layer including a first phase change material having a transition temperature of from about −10° C. to about 40° C., and a second layer including a second phase change material having a transition temperature of from about 35° C. to about 65° C. The first layer is joined to the second layer to form at least a partial enclosure having an opening through which a thermoactive material may be inserted and removed.

Claims (31)

1. A flexible thermal therapy sleeve comprising:

a first layer including a first phase change material having a transition temperature of from about −10° C. to about 40° C.; and

a second layer including a second phase change material having a transition temperature of from about 35° C. to about 65° C.,

wherein the first layer is joined to the second layer to form at least a partial enclosure having an opening through which a thermoactive material may be inserted and removed.

2. The sleeve of claim 1 , wherein the first phase change material is selected from the group consisting of n-eicosane, n-hemeicosane, n-docosane, n-tricosane, n-tetracosane, n-pentacosane, n-hexacosane, n-heptacosane, n-octacosane, and a combination thereof.

3. The sleeve of claim 1 , wherein the second phase change material is selected from the group consisting of n-tridecane, n-tetradecane, n-pentadecane, n-hexadecane, n-heptadecane, n-octadecane, n-nonadecane, n-eicosane, and a combination thereof.

4. A flexible thermal therapy sleeve comprising:

a first layer including a first phase change material and a second phase change material, the first phase change material having a transition temperature of from about −10° C. to about 40° C. and the second phase change material having a transition temperature of from about 35° C. to about 65° C.; and

a second layer joined to the first layer to form at least a partial enclosure having an opening through which a thermoactive material may be inserted and removed.

5. The sleeve of claim 1 , wherein the first phase change material is selected from the group consisting of n-eicosane, n-hemeicosane, n-docosane, n-tricosane, n-tetracosane, n-pentacosane, n-hexacosane, n-heptacosane, n-octacosane, and a combination thereof.

6. The sleeve of claim 1 , wherein the second phase change material is selected from the group consisting of n-tridecane, n-tetradecane, n-pentadecane, n-hexadecane, n-heptadecane, n-octadecane, n-nonadecane, n-eicosane, and a combination thereof.

7. The sleeve of claim 4 , wherein the second layer comprises a third phase change material.

8. The sleeve of claim 7 , wherein the third phase change material has a transition temperature of from about −10° C. to about 40° C.

9. The sleeve of claim 7 , wherein the third phase change material has a transition temperature of from about 35° C. to about 65° C.

10. A thermal therapy system having an extended therapeutic duration comprising:

a thermoactive material comprising a chemical pack, the pack including a first phase change material, a solute, and a solvent, wherein the solute and the solvent are separated by a membrane, where the rupturing of the membrane causes the combination of the solute and solvent and produces an endothermic reaction or an exothermic reaction; and

a flexible sleeve including a first layer and a second layer, the first layer including a second phase change material having a transition temperature of from about −10° C. to about 40° C. and a third phase change material having a transition temperature of from about 35° C. to about 65° C.,

wherein the first layer is joined to the second layer to form at least a partial enclosure having an opening through which the thermoactive material may be inserted and removed.

11. The system of claim 10 , wherein the solute comprises ammonium nitrate.

12. The system of claim 10 , wherein the first phase change material has a transition temperature of from about −10° C. to about 40° C.

13. The system of claim 10 , wherein the first phase change material is selected from the group consisting of n-tridecane, n-tetradecane, n-pentadecane, n-hexadecane, n-heptadecane, n-octadecane, n-nonadecane, n-eicosane, and a combination thereof.

14. The system of claim 10 , wherein the solute comprises calcium chloride.

15. The system of claim 10 , wherein the first phase change material has a transition temperature of from about 35° C. to about 65° C.

16. The system of claim 10 , wherein the first phase change material is selected from the group consisting of n-eicosane, n-hemeicosane, n-docosane, n-tricosane, n-tetracosane, n-pentacosane, n-hexacosane, n-heptacosane, n-octacosane, and a combination thereof.

17. A thermal therapy system having an extended therapeutic duration comprising:

a thermoactive material comprising a chemical pack, the pack including a first phase change material, a solute, and a solvent, wherein the solute and the solvent are separated by a membrane, where the rupturing of the membrane causes the combination of the solute and solvent and produces an endothermic reaction or an exothermic reaction; and

a flexible sleeve comprising a first layer and a second layer, the first layer including a second phase change material having a transition temperature of from about −10° C. to about 40° C., and the second layer including a third phase change material having a transition temperature of from about 35° C. to about 65° C.,

wherein the first layer is joined to the second layer to form at least a partial enclosure having an opening through which the thermoactive material may be inserted and removed.

18. The system of claim 17 , wherein the first phase change material has a transition temperature of from about −10° C. to about 40° C.

19. The system of claim 17 , wherein the first phase change material has a transition temperature of from about 35° C. to about 65° C.

20. The system of claim 17 , wherein the first phase change material, the second phase change material, and the third phase change material are selected from the group consisting of n-eicosane, n-hemeicosane, n-docosane, n-tricosane, n-tetracosane, n-pentacosane, n-hexacosane, n-heptacosane, n-octacosane, n-tridecane, n-tetradecane, n-pentadecane, n-hexadecane, n-heptadecane, n-octadecane, n-nonadecane, n-eicosane, and a combination thereof.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2026
From: JPMORGAN CHASE BANK, N.A.
To: O&M HALYARD, INC.; OWENS & MINOR DISTRIBUTION, INC.
Reel/Frame 074212/0570 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2026
From: BANK OF AMERICA, N.A.
To: MEDICAL ACTION INDUSTRIES INC.; O&M HALYARD, INC.; OWENS & MINOR DISTRIBUTION, INC.
Reel/Frame 074203/0026 →
RELEASE OF SECURITY INTEREST Recorded Jun 30, 2022
From: CITIBANK, N.A.
To: AVENT, INC.; AVANOS MEDICAL SALES, LLC
Reel/Frame 060557/0062 →
PATENT SECURITY AGREEMENT Recorded Mar 29, 2022
From: O&M HALYARD, INC.; OWENS & MINOR DISTRIBUTION, INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 059541/0024 →
PATENT SECURITY AGREEMENT Recorded Mar 12, 2021
From: MEDICAL ACTION INDUSTRIES INC.; OWENS & MINOR DISTRIBUTION, INC.; O&M HALYARD, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 055582/0407 →
RELEASE OF SECURITY INTEREST Recorded Mar 12, 2021
From: BANK OF AMERICA, N.A.
To: OWENS & MINOR DISTRIBUTION, INC.; MEDICAL ACTION INDUSTRIES, INC.; O&M HALYARD, INC.
Reel/Frame 055583/0722 →
INTELLECTUAL PROPERTY SECURITY INTEREST ASSIGNMENT AGREEMENT Recorded Jan 23, 2019
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: CITIBANK, N.A.
Reel/Frame 048173/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2018
From: AVENT, INC.
To: O&M HALYARD, INC.
Reel/Frame 046324/0736 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded May 8, 2018
From: O&M HALYARD, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 046100/0646 →
RELEASE OF SECURITY INTEREST Recorded May 1, 2018
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: AVENT, INC.
Reel/Frame 046476/0710 →
SECURITY INTEREST Recorded Apr 6, 2015
From: AVENT, INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 035375/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2015
From: KIMBERLY-CLARK WORLDWIDE, INC.
To: AVENT, INC.
Reel/Frame 034754/0424 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2003
From: AGARWAL, NAVEEN; FISH, JEFFREY E.; WEART, ILONA F.; WILLIS, JEFFREY M.
To: KIMBERLY-CLARK WORLDWIDE, INC.
Reel/Frame 013899/0081 →